Hoffmann-La Roche: Multiple Sclerosis, Relapsing-Remitting trials

The registry lists 14 Multiple Sclerosis, Relapsing-Remitting studies with Hoffmann-La Roche as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 1 2Phase 2 3Phase 3 6No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple SclerosisRecruitingNCT07827586
• A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Not yet recruitingNCT07503340Phase 2
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Active, not recruitingNCT05123703Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04544436Phase 3Results posted
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)TerminatedNCT03085810Phase 3Results posted
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)CompletedNCT02861014Phase 3Results posted
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)CompletedNCT02637856Phase 3Results posted
• A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple SclerosisCompletedNCT02545868Phase 3Results posted
• A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00676715Phase 2Results posted
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisActive, not recruitingNCT07667322Phase 1
• Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple SclerosisSuspendedNCT05949580
• Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis ConditionCompletedNCT02598167
• Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.CompletedNCT01808885Phase 1
• A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple SclerosisCompletedNCT00097188Phase 2